Cargando…

Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer

Canonical prefoldin is a protein cochaperone composed of six different subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN i...

Descripción completa

Detalles Bibliográficos
Autores principales: Peñate, Xenia, Praena-Fernández, Juan Manuel, Romero Pareja, Pedro, Enguix-Riego, María del Valle, Payán-Bravo, Laura, Vieites, Begoña, Gomez-Izquierdo, Lourdes, Jaen Olasolo, Javier, Rivin del Campo, Eleonor, Reyes, Jose Carlos, Chávez, Sebastián, Lopez Guerra, Jose Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225921/
https://www.ncbi.nlm.nih.gov/pubmed/32344577
http://dx.doi.org/10.3390/cancers12041052
_version_ 1783534165975629824
author Peñate, Xenia
Praena-Fernández, Juan Manuel
Romero Pareja, Pedro
Enguix-Riego, María del Valle
Payán-Bravo, Laura
Vieites, Begoña
Gomez-Izquierdo, Lourdes
Jaen Olasolo, Javier
Rivin del Campo, Eleonor
Reyes, Jose Carlos
Chávez, Sebastián
Lopez Guerra, Jose Luis
author_facet Peñate, Xenia
Praena-Fernández, Juan Manuel
Romero Pareja, Pedro
Enguix-Riego, María del Valle
Payán-Bravo, Laura
Vieites, Begoña
Gomez-Izquierdo, Lourdes
Jaen Olasolo, Javier
Rivin del Campo, Eleonor
Reyes, Jose Carlos
Chávez, Sebastián
Lopez Guerra, Jose Luis
author_sort Peñate, Xenia
collection PubMed
description Canonical prefoldin is a protein cochaperone composed of six different subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in LC translates into the clinic. First, the mRNA expression of 518 non-small cell LC (NSCLC) cases from The Cancer Genome Atlas (TCGA) database was evaluated. Patients with PFDN1 overexpression had lower overall survival (OS; 45 vs. 86 months; p = 0.034). We then assessed the impact of PFDN expression on outcome in 58 NSCLC patients with available tumor tissue samples. PFDN1, 3, and 5 overexpression were found in 38% (n = 22), 53% (n = 31), and 41% (n = 24) of tumor samples. PFDN1, 3, and 5 overexpression were significantly associated with lower OS, lower disease-free survival (DFS), and lower distant metastasis-free survival (DMFS) for PFDN1 and 3 with a trend for PFDN5. In multivariate analysis, PFDN5 retained significance for OS (hazard ratio (HR) 2.56; p = 0.007) and PFDN1 for DFS (HR 2.53; p = 0.010) and marginally for DMFS (HR 2.32; p = 0.053). Our results indicate that protein response markers, such as PFDN1, 3, and 5, may complement mRNA signatures and be useful for determining the most appropriate therapy for NSCLC patients.
format Online
Article
Text
id pubmed-7225921
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72259212020-05-18 Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer Peñate, Xenia Praena-Fernández, Juan Manuel Romero Pareja, Pedro Enguix-Riego, María del Valle Payán-Bravo, Laura Vieites, Begoña Gomez-Izquierdo, Lourdes Jaen Olasolo, Javier Rivin del Campo, Eleonor Reyes, Jose Carlos Chávez, Sebastián Lopez Guerra, Jose Luis Cancers (Basel) Brief Report Canonical prefoldin is a protein cochaperone composed of six different subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in LC translates into the clinic. First, the mRNA expression of 518 non-small cell LC (NSCLC) cases from The Cancer Genome Atlas (TCGA) database was evaluated. Patients with PFDN1 overexpression had lower overall survival (OS; 45 vs. 86 months; p = 0.034). We then assessed the impact of PFDN expression on outcome in 58 NSCLC patients with available tumor tissue samples. PFDN1, 3, and 5 overexpression were found in 38% (n = 22), 53% (n = 31), and 41% (n = 24) of tumor samples. PFDN1, 3, and 5 overexpression were significantly associated with lower OS, lower disease-free survival (DFS), and lower distant metastasis-free survival (DMFS) for PFDN1 and 3 with a trend for PFDN5. In multivariate analysis, PFDN5 retained significance for OS (hazard ratio (HR) 2.56; p = 0.007) and PFDN1 for DFS (HR 2.53; p = 0.010) and marginally for DMFS (HR 2.32; p = 0.053). Our results indicate that protein response markers, such as PFDN1, 3, and 5, may complement mRNA signatures and be useful for determining the most appropriate therapy for NSCLC patients. MDPI 2020-04-24 /pmc/articles/PMC7225921/ /pubmed/32344577 http://dx.doi.org/10.3390/cancers12041052 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Peñate, Xenia
Praena-Fernández, Juan Manuel
Romero Pareja, Pedro
Enguix-Riego, María del Valle
Payán-Bravo, Laura
Vieites, Begoña
Gomez-Izquierdo, Lourdes
Jaen Olasolo, Javier
Rivin del Campo, Eleonor
Reyes, Jose Carlos
Chávez, Sebastián
Lopez Guerra, Jose Luis
Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer
title Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer
title_full Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer
title_fullStr Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer
title_full_unstemmed Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer
title_short Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer
title_sort overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225921/
https://www.ncbi.nlm.nih.gov/pubmed/32344577
http://dx.doi.org/10.3390/cancers12041052
work_keys_str_mv AT penatexenia overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT praenafernandezjuanmanuel overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT romeroparejapedro overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT enguixriegomariadelvalle overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT payanbravolaura overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT vieitesbegona overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT gomezizquierdolourdes overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT jaenolasolojavier overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT rivindelcampoeleonor overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT reyesjosecarlos overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT chavezsebastian overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer
AT lopezguerrajoseluis overexpressionofcanonicalprefoldinassociateswiththeriskofmortalityandmetastasisinnonsmallcelllungcancer